A topic in the Open Knowledge Graph — a free, open map of 15,290 topics and the order to learn them in.
The serotonin transporter (SERT) is the primary mechanism for removing serotonin from synaptic space, enabling rapid signal termination. Selective serotonin reuptake inhibitors (SSRIs) competitively block SERT, increasing synaptic serotonin availability without directly activating receptors. SERT function is modulated by phosphorylation and trafficking, creating individual differences in transporter density that correlate with treatment response and side effects.
From your prerequisite work, you know that neurotransmitter signaling must be terminated quickly — a synapse that stays on indefinitely cannot encode timing or carry meaningful information. For many neurotransmitters, the primary termination mechanism is reuptake: the presynaptic neuron recaptures the released transmitter using dedicated transporter proteins embedded in its membrane. For serotonin, that transporter is SERT (the serotonin transporter, encoded by the gene SLC6A4). SERT works like a molecular vacuum, pulling serotonin back from the synaptic cleft into the presynaptic terminal, where it can be repackaged into vesicles for reuse or degraded by MAO enzymes.
SERT does not simply open a pore — it is a secondary active transporter that couples serotonin uptake to the co-transport of Na⁺ (following its electrochemical gradient) and Cl⁻, and the counter-transport of K⁺. Each transport cycle physically moves one serotonin molecule from the extracellular space into the cytoplasm. The consequence is that SERT activity is tunable: phosphorylation by protein kinases (particularly PKC and PKG) can reduce the number of SERT molecules in the membrane by triggering internalization, while dephosphorylation promotes SERT surface expression. This means serotonergic signaling strength is not static — it varies with the intracellular signaling environment.
SSRIs — fluoxetine, sertraline, escitalopram, and related drugs — bind to SERT and block the transporter's binding site for serotonin without being transported themselves. This is competitive inhibition: serotonin and the SSRI compete for the same site, and with SSRI present, less serotonin is removed per unit time. The result is elevated serotonin concentration in the synaptic cleft and prolonged receptor activation downstream. Critically, SSRIs do not directly activate serotonin receptors. They work indirectly, by changing the environment in which those receptors operate. This distinction matters: SSRIs have no immediate psychoactive effect comparable to direct agonists; their clinical effects on mood and anxiety typically take two to four weeks, likely reflecting downstream receptor desensitization and adaptive changes in neural circuits rather than the acute SERT block itself.
Individual differences in SERT expression — driven by genetic variants in the promoter region (the 5-HTTLPR polymorphism is the best-studied example) and by the phosphorylation-trafficking mechanisms mentioned above — help explain why patients respond differently to SSRI treatment. Someone with lower basal SERT density has less transporter capacity to block, meaning the pharmacological effect of the same dose differs from someone with high transporter density. Understanding SERT as a regulated, variable-density system rather than a fixed molecular constant is essential to making sense of the variability in clinical response that characterizes antidepressant pharmacotherapy.